Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Genetic Technologies restructures to focus on growth in the US

  • In News
  • July 26, 2024
  • Sidra Surmed
Genetic Technologies restructures to focus on growth in the US

Ever thought about how your chin resembles your father? Or your eye colour resembles your great grandmother – it’s all in the genes right! Genetics and DNA lie at the heart of biological sciences. 

Genetic Technologies (ASX: GTG) is initiating a strategic transformation to enhance prospects and financial stability. The plan involves operational restructuring to adopt the capital-light model, and expand their clientele in the United States. This involves outsourcing laboratory operations and reducing costs.

GTG is sharpening its focus on its core units, EasyDNA and geneType, to streamline operations and cut costs. By outsourcing its lab work, GTG plans to slash monthly expenses from $800,000 to under $200,000, boosting financial efficiency.

To support this transition, GTG is securing an $800,000 short-term loan and raising at least $2 million through a 2 for 3 Rights Issue at 4 cents per share, with an attached 1:1 option. This capital will fuel ongoing innovation, particularly in geneType’s serious disease risk tests, backed by over $50 million in R&D funding.

With rising numbers of high risk diseases like cancer, molecular diagnostics company GTG piloted its risk assessment test geneType in breast screening centres across the US earlier this year. The Company has established a clinical implementation study with breast imaging centres in New York, Miami and Houston. 

In H1 FY24, the Company recorded cash receipts of $3.9 million and launched a digital transformation strategy. A record number of geneType tests were processed, with six times more commercial samples received compared to the prior period. Whilst the Company launched the Hereditary Breast & Ovarian Cancer Risk Assessment Test (HBOC) via an exclusive Santa Monica event for select clinicians.

In addition to the entitlement offer, a top-up offer allows eligible shareholders to purchase additional shares. Although directors are committed to investing $500,000, the offer is not fully underwritten. Detailed terms will be outlined in a prospectus to be lodged around August 12, 2024. 

GTG shares reached a low of $0.041 in early morning trade which was a 6.82% decrease on the previous $0.045 close price. 

 

  • About
  • Latest Posts
Sidra Surmed
Sidra is a Business Writer with The Sentiment
Latest posts by Sidra Surmed (see all)
  • Interest in captioning tech sees jump in earnings for AI-Media - August 29, 2024
  • Despite construction industry challenges, Duratec delivers earnings growth - August 28, 2024
  • AI-powered road safety solutions pave the way for Acusensus revenue bump - August 27, 2024
  •  
  •  
  •  
  •  
  • asx gtg
  • breast screening
  • easyDNA
  • genetic technologies
  • GeneType
  • lab
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    March 7, 2025, 6:14 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/genetic-stability-testing-service

    Reply
  • About
  • Latest Posts
Sidra Surmed
Sidra is a Business Writer with The Sentiment
Latest posts by Sidra Surmed (see all)
  • Interest in captioning tech sees jump in earnings for AI-Media - August 29, 2024
  • Despite construction industry challenges, Duratec delivers earnings growth - August 28, 2024
  • AI-powered road safety solutions pave the way for Acusensus revenue bump - August 27, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Sidra Surmed
Sidra is a Business Writer with The Sentiment
Latest posts by Sidra Surmed (see all)
  • Interest in captioning tech sees jump in earnings for AI-Media - August 29, 2024
  • Despite construction industry challenges, Duratec delivers earnings growth - August 28, 2024
  • AI-powered road safety solutions pave the way for Acusensus revenue bump - August 27, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.